The guys buying those units today at .07 share are expecting to sell for a higher price, and currently their new shares are not registered and can not be sold until they are registered. They may have further selling restrictions we do not know of, but they won't be selling for less than .07, so that sets a floor there. Also it increases the cash on hand by 500% or more (does someone know what cash on hand was?, it may be more like 1000% increase in cash). On going losses per share will drop due to dilution (looks good on the books to new investors). They now have cash they badly needed, and have added several items to the drug pipeline, at minimal cost IMHO. I am impressed with what they have done.
But as a wise man once said: "We will see" I doubled my shares today buying at .065, but what puzzles me is why the offer price sat unchanged almost all day today. Tomorrow may change this as people catch the news over night that do not day trade. I had my old shares on a sell order at .08 till this morning's news. I changed that sell order to .15 today, and bought more at .065.
But as a wise man once said: "We will see" I doubled my shares today buying at .065, but what puzzles me is why the offer price sat unchanged almost all day today. Tomorrow may change this as people catch the news over night that do not day trade. I had my old shares on a sell order at .08 till this morning's news. I changed that sell order to .15 today, and bought more at .065.
Recent TGTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:33:42 PM
- TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 03/09/2026 11:30:00 AM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting • GlobeNewswire Inc. • 03/06/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2026 10:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:08:34 PM
- TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 02/17/2026 12:30:00 PM
- TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis • GlobeNewswire Inc. • 02/08/2026 09:17:55 PM
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 02/06/2026 12:30:00 PM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 01/27/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 09:27:48 PM
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones • GlobeNewswire Inc. • 01/13/2026 09:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:16:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:15:33 PM
- TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/07/2026 12:30:00 PM
- TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference • GlobeNewswire Inc. • 11/28/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/25/2025 10:31:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/24/2025 09:04:15 PM
- TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies • GlobeNewswire Inc. • 11/19/2025 01:30:00 PM
- TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit • GlobeNewswire Inc. • 11/10/2025 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2025 10:01:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2025 09:31:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2025 12:34:54 PM
